Inactive Instrument

Other languages Aytu Bioscience Inc Nasdaq

Equities

US0547544033

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	15/02
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	27/23/27
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	26/23/26
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer	07/23/07
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	28/23/28
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/23/28
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	31/23/31
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	10/23/10
Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain to the Board of Directors	09/23/09
Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	12/23/12
Wall Street Set to Open Slightly Lower Ahead of Fed Meeting, US Factory Order Data	02/23/02
Aytu BioPharma Subleases A Portion of Its Manufacturing Facility	01/23/01
Aytu BioPharma Receives FDA Approval to Transfer Manufacturing Site of Adzenys XR-ODT	27/23/27
Aytu Biopharma, Inc. Announces Successfully Completion of Cotempla XR-ODT Bioequivalence Study	27/23/27
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	22/23/22
Aytu BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement	25/23/25
Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients	10/23/10
Top Premarket Decliners	28/22/28
Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022	28/22/28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aytu Bioscience Inc Nasdaq

Equities

US0547544033

Other languages

Filters